Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furosemide Strategies in Type 1 Cardiorenal Syndrome
NCT04393493Phase 2Completed
- Sponsor
- Hospital Civil de Guadalajara
- Start
- Jul 2017
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of furosemide in Cardiorenal syndrome type 1 (CRS-1), sponsored by Hospital Civil de Guadalajara. Primary endpoint: Number of Participants With Renal Function Recovery Defined as a Return to Individual Baseline Serum Creatinine Values at 96 hours. Started Jul 2017; status: completed.
02
Drugs
furosemide
03
Conditions
Cardiorenal syndrome type 1 (CRS-1)
Beyond the preview
Go deeper on NCT04393493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04393493.